Junshi Bio announced that the company's product Toripalimab injection has successfully added 4 new indications to the Class B scope of the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Pharmaceutical Directory". The new version of the national medical insurance directory will be officially implemented on January 1, 2025.
君实生物：特瑞普利单抗新增4项适应症纳入国家医保目录
Junshi Bio: Toripalimab has added 4 new indications to the national medical insurance directory.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated